Trial
NCT00234000
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
CTI BioPharma; Celgene Corporation
Condition
Leukemia
Intervention
arsenic trioxide
Why stopped
The study was closed due to poor enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-31